Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.

You may also be interested in...

Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care

The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.

Advanced Tissue Sciences Pursuing Dermagraft Cardiac Indications

Pursuit of cardiovascular indications for Advanced Tissue Sciences' Dermagraft fibroblast tissue repair technology is likely to hinge upon finding a joint venture partner for the product, according to the La Jolla, California-based company.

Smith & Nephew Exogen 2000 Labeling For Non-Union Fracture Approved

Smith & Nephew will employ its 300-person direct sales force to promote an expanded indication for the Exogen 2000 low-intensity pulsed ultrasound device for treatment of non-union bone fractures, a market valued at roughly $110 mil.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts